Abstract: Background: Successful highly active antiretroviral therapy (HAART) regimens have resulted in substantial improvements in the systemic health of HIV infected persons and increased survival times. Despite increased systemic health, the prevalence of minor HIV-associated cognitive impairment appears to be rising with increased longevity, and it remains to be seen what functional outcomes will result from these improvements. Cognitive impairment can dramatically impact functional ability and day-to-day productivity. We assessed the relationship of quality of life (QOL) and neuropsychological functioning with successful HAART treatment. Methods: In a prospective longitudinal study, subjects were evaluated before instituting HAART (naï...
OBJECTIVE: The objective of the current study is to integrate results from extensive neuropsychologi...
The association between HIV-associated neurocognitive impairment (NCI) and health-related quality of...
Background. AIDS Clinical Trials Group (ACTG) A5199 compared the neurological and neuropsychological...
Abstract: Background: Successful highly active antiretroviral therapy (HAART) regimens have resulted...
Background: Despite the use of combination antiretroviral therapy, HIV associated neurocognitive imp...
The advent of highly active antiretroviral therapy (HAART) has resulted in significant reductions in...
The objective of this study was to describe the occurrence of HIV dementia and neuropsychological te...
Quality of life (QoL) is recognized as an essential end point in the disease management of chronic c...
ABSTRACT BACKGROUND: The human immunodeficiency virus (HIV) can give rise to a spectrum of neuropsyc...
Quality of life (QoL) is recognized as an essential end point in the disease management of chronic c...
OBJECTIVE: Prior studies have shown improved neurocognition with initiation of antiretroviral treatm...
Study background: The introduction and availability of highly active antiretroviral therapy (HAART) ...
Currently, neuropsychological impairment among HIV+ patients on antiretroviral therapy leads to a re...
Background: HIV-associated cognitive impairment occurs even in the early stages of infection. Short-...
BACKGROUND: Cognitive impairment (CI) in people living with HIV (PLWH) is an important health concer...
OBJECTIVE: The objective of the current study is to integrate results from extensive neuropsychologi...
The association between HIV-associated neurocognitive impairment (NCI) and health-related quality of...
Background. AIDS Clinical Trials Group (ACTG) A5199 compared the neurological and neuropsychological...
Abstract: Background: Successful highly active antiretroviral therapy (HAART) regimens have resulted...
Background: Despite the use of combination antiretroviral therapy, HIV associated neurocognitive imp...
The advent of highly active antiretroviral therapy (HAART) has resulted in significant reductions in...
The objective of this study was to describe the occurrence of HIV dementia and neuropsychological te...
Quality of life (QoL) is recognized as an essential end point in the disease management of chronic c...
ABSTRACT BACKGROUND: The human immunodeficiency virus (HIV) can give rise to a spectrum of neuropsyc...
Quality of life (QoL) is recognized as an essential end point in the disease management of chronic c...
OBJECTIVE: Prior studies have shown improved neurocognition with initiation of antiretroviral treatm...
Study background: The introduction and availability of highly active antiretroviral therapy (HAART) ...
Currently, neuropsychological impairment among HIV+ patients on antiretroviral therapy leads to a re...
Background: HIV-associated cognitive impairment occurs even in the early stages of infection. Short-...
BACKGROUND: Cognitive impairment (CI) in people living with HIV (PLWH) is an important health concer...
OBJECTIVE: The objective of the current study is to integrate results from extensive neuropsychologi...
The association between HIV-associated neurocognitive impairment (NCI) and health-related quality of...
Background. AIDS Clinical Trials Group (ACTG) A5199 compared the neurological and neuropsychological...